Serotonin 

 448 Products   448 Products   1070 Diseases   113911 News 


«12...4142434445464748495051...11171118»
  • ||||||||||  fentanyl citrate / Generic mfg.
    Journal:  Understand the FDA-cleared fentanyl testing: A clinical evaluation of the SEFRIA fentanyl immunoassay. (Pubmed Central) -  May 21, 2024   
    These results show that the IRE1?-XBP1 system enhances viral replication and cytokine expression and may represent a potential therapeutic target in SARS-CoV-2 severe pneumonia. By applying the new cutoff and including an interference comment to positive screening results, the FP rate was reduced from initial 38 % to 7.5 % (17?% times 56?%).
  • ||||||||||  duloxetine / Generic mfg.
    Preclinical, Journal:  Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans. (Pubmed Central) -  May 21, 2024   
    Changes in TMEM161B expression level was also observed in blood of MDD patients when compared with controls, and after 8-week treatment with duloxetine, mainly in good responders to treatment. Altogether, our results introduce H/Rouen and H-TST as the two first polygenic animal models of MDD and demonstrate their ability to identify biomarkers of the disease and to develop rapid and effective antidepressant medications.
  • ||||||||||  ulotaront (SEP-363856) / Otsuka, PsychoGenics
    Journal:  TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. (Pubmed Central) -  May 21, 2024   
    Furthermore, we show that ulotaront regulates excitation-inhibition balance in the striatum by specifically modulating glutamatergic, but not GABAergic, spontaneous synaptic events. These findings expand the mechanistic circuit hypothesis of ulotaront and TAAR1 agonists, which may be uniquely positioned to normalize both the excessive dopaminergic tone and regulate abnormal glutamatergic function associated with schizophrenia.
  • ||||||||||  citalopram / Generic mfg.
    Trial completion, Trial completion date:  CABIN: Combined Antidepressant and Behavioural Intervention (clinicaltrials.gov) -  May 21, 2024   
    P=N/A,  N=134, Completed, 
    Pimavanserin's MR appears to be comparable to or lower than other atypical antipsychotics prescribed for PDP, including quetiapine. Recruiting --> Completed | Trial completion date: May 2023 --> Nov 2023
  • ||||||||||  amitriptyline / Generic mfg.
    Journal:  Gastroenterology/Hepatology: What You May Have Missed in 2023. (Pubmed Central) -  May 20, 2024   
    The authors feature a randomized trial about amitriptyline as treatment for patients with irritable bowel syndrome by primary care providers and bring you news about new biologic agents for inflammatory bowel disease and eosinophilic esophagitis. Finally, they review 2 important articles on new terminology and management of metabolic dysfunction-associated fatty liver disease.
  • ||||||||||  quetiapine / Generic mfg.
    Journal:  Daily quetiapine after severe TBI improves learning and memory. (Pubmed Central) -  May 20, 2024   
    Post-TBI QTP reduces brain edema and improves spatial learning and memory with a potential dose dependence impact benefiting memory up to 14 days. These data suggest an unanticipated QTP benefit following brain injury that should be specifically explored.
  • ||||||||||  Vyleesi (bremelanotide) / Palatin Technologies, Addyi (flibanserin) / Sprout Pharma
    Review, Journal:  Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. (Pubmed Central) -  May 20, 2024   
    Further research with the most suitable clinical endpoints and consideration of patient factors are crucial before widespread adoption of flibanserin and bremelanotide. Pharmacists are encouraged to embrace this opportunity to provide premenopausal HSDD care in ambulatory and community practice settings.
  • ||||||||||  olanzapine / Generic mfg.
    Review, Journal:  Olanzapine-induced cardiomyopathy: A mimicker of obesity cardiomyopathy? (Pubmed Central) -  May 20, 2024   
    Early identification and management of olanzapine-induced cardiomyopathy can improve patient outcomes. Further research is needed to elucidate the precise mechanisms behind this adverse effect and to develop optimized treatment strategies for patients requiring antipsychotic therapy.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Trial completion date, Trial initiation date, Trial primary completion date:  BPH Botox: Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity (clinicaltrials.gov) -  May 20, 2024   
    P=N/A,  N=100, Not yet recruiting, 
    In conclusion, our data suggest that sertraline hydrochloride, an antidepressant, can potentially be used for the treatment of breast cancer. Trial completion date: Aug 2024 --> Dec 2025 | Initiation date: Dec 2023 --> Jan 2025 | Trial primary completion date: May 2024 --> Nov 2025
  • ||||||||||  chlorpromazine / Generic mfg.
    Review, Journal:  The Psychotherapy of Schizophrenia: A Review of the Evidence for Psychodynamic and Nonpsychodynamic Treatments. (Pubmed Central) -  May 20, 2024   
    Following the discovery of chlorpromazine's effectiveness as a treatment for schizophrenia in the 1950s, a gradual shift away from psychotherapeutic and toward biological methods of investigation has ensued...There is evidence to support the use of both types of therapies though these orientations generally differ in their views on the role of psychological factors in the etiology of schizophrenia. It is argued that a pluralistic or biopsychosocial model of schizophrenia is necessary to account for the complexity of the disease and to provide the most effective treatment.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Journal:  ADME/PK Insights of Crocetin: A Molecule Having an Unusual Chemical Structure with Druglike Features. (Pubmed Central) -  May 20, 2024   
    However, aqueous solubility, chemical stability, plasma protein binding, and P-gp induction are some concerns associated with this molecule that should be taken into consideration during its further development. Overall results indicate favorable ADME/PK behavior and potential druggable candidature of crocetin.
  • ||||||||||  fluoxetine / Generic mfg.
    Journal:  Ecotoxicological effects of ketoprofen and fluoxetine and their mixture in an aquatic microcosm. (Pubmed Central) -  May 19, 2024   
    The structure of micro-eukaryotic communities was altered in the fluoxetine-containing systems, whereas the structure of bacterial communities was affected to a greater extent by the mixture. The disruptions to the equilibrium of the microcosm demonstrate the ecological risk these compounds pose to aquatic ecosystems.
  • ||||||||||  citalopram / Generic mfg., sertraline / Generic mfg.
    Journal:  Dysregulation of adipogenesis and disrupted lipid metabolism by the antidepressants citalopram and sertraline. (Pubmed Central) -  May 19, 2024   
    Our findings suggest lysosomal dysfunction and disrupted lipid metabolism in mature adipocytes, leading to excessive phospholipid synthesis. Moreover, important adipogenic processes are inhibited, potentially leading to dysfunctional adipocytes, which might have implications in maintenance of a healthy metabolic balance.
  • ||||||||||  Journal:  Antipsychotic medications and sleep problems in patients with schizophrenia. (Pubmed Central) -  May 19, 2024   
    Prevalence of sleep problems is markedly related to the antipsychotic medication the patient uses. These findings underline the importance of considering and assessing sleep problems when treating schizophrenia patients with antipsychotics.
  • ||||||||||  olanzapine / Generic mfg.
    Preclinical, Journal:  Olanzapine-induced weight gain and lipid dysfunction in mice between different gender. (Pubmed Central) -  May 19, 2024   
    This lipidome profiling study not only visualizes changes in lipid metabolism in liver tissue but also provides a foundation for understanding the regulatory pathways and mechanisms involved in olanzapine-induced lipid metabolism disorders. Furthermore, this study demonstrates differences in lipid metabolism between males and females, providing a reference for clinical treatment regimen selection.
  • ||||||||||  fosaprepitant / Generic mfg.
    Trial completion date:  AFTR NV RCT: Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) -  May 19, 2024   
    P2/3,  N=250, Not yet recruiting, 
    A low antiemetic response was observed with ondansetron in the presence of the AA genotype (rs16947 A/G) and the AA genotype (rs1065852 A/G), and a low therapeutic response was found with palonosetron in the presence of the GG genotype (rs16947 A/G) in laparoscopic cholecystectomy. Trial completion date: May 2025 --> Dec 2024
  • ||||||||||  ondansetron / Generic mfg.
    Journal, Lipid Nanoparticle:  Examination Of The Effects Of Vitexin And Vitexin-Loaded Solid Lipid Nanoparticles On Neuropathic Pain And Possible Mechanisms Of Action. (Pubmed Central) -  May 18, 2024   
    Ketanserin, ondansetron, WAY-100635, yohimbine and bicuculin, which are antagonists of receptors on pain pathways...In conclusion, vitexin and vitexin-loaded formulation have the potential for clinical use in neuropathic pain management, and different pain pathways contributed to this effect. And also, it is thought that vitexin-loaded SLN formulation is more effective than pure vitexin, which will provide an advantage in treatment.
  • ||||||||||  chlorpromazine / Generic mfg.
    Journal:  Cerebellar Effects on Abnormal Psychomotor Function Are Mediated by Processing Speed in Psychosis Spectrum. (Pubmed Central) -  May 18, 2024   
    Models included intracranial volume, age, sex, and chlorpromazine equivalents as covariates...Establishing such relationships is critical for intervention research, such as TMS. Future work will employ more dimensional measures of psychomotor disturbance and cognitive processes to capture normative and aberrant brain-behavior-symptom relationships and may also determine the magnitude of these relationships within subtypes of psychosis (e.g., disorganized behavior, catatonia).
  • ||||||||||  Review, Journal:  Evidence for Therapeutic Drug Monitoring of Atypical Antipsychotics. (Pubmed Central) -  May 18, 2024   
    Non-response to therapeutic doses, uncertain adherence to medication, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM of SGAs. This review aims to summarize an overview of the current knowledge and evidence of the possibilities to tailor the dosage of selected SGAs using TDM, including the necessary pharmacokinetic parameters for personalised pharmacotherapy.